Neuronetics Inc. (STIM) to Join Russell 2000 and Russell 3000 Indexes

Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.

The broad-market Russell 3000® Index includes the largest 3,000 U.S. public companies by market capitalization. The Russell 2000® Index is a subset of the broader Russell 3000® Index limited to small-cap companies. The indexes are reconstituted annually by re-ranking companies based on total market capitalization as of the reconstitution rank date, which was April 30, 2025 this year. Index membership remains in place for one year and results in automatic inclusion in the relevant growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

"This inclusion in the Russell 3000® and Russell 2000® Indexes represents an important validation of our strategic vision and operational execution," said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. "As we continue expanding access to innovative mental health treatments through our integrated approach—combining our leading NeuroStar technology with our growing Greenbrook clinic network—this milestone enhances our visibility among institutional investors and reflects the significant progress we've made in transforming how mental healthcare is delivered. With our path to positive cash flow this year and our proven operating model driving strong growth, we're well-positioned to continue delivering value for both patients and shareholders."

You May Also Be Interested In

• FDA clears Dexcom's over-the-counter glucose monitor for children
• Super League Enterprise (SLE) files for 1.07M share offering by selling stockholders
• Nutrien warns shareholders about below-market mini-tender offer